Clinical Trial Update: SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating SGLT2 inhibition to reduce cardiovascular endpoints in hypertension and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: Prof. Dr. med. Ingo Eitel | Conditions: Atrial Hypertension | Phase 3 | Status: RECRUITING